IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 20
Summary
- Conditions
- Hypopharynx Squamous Cell Carcinoma
- Larynx Squamous Cell Carcinoma
- Metastatic Squamous Cell Carcinoma
- Oral Cavity Squamous Cell Carcinoma
- Oropharynx Squamous Cell Carcinoma
- Paranasal Sinus Squamous Cell Carcinoma
- Squamous Cell Carcinoma
- Squamous Cell Carcinoma of the Head and Neck
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Study Population: Patients with histologically or cytologically confirmed recurrent or metastatic squamous cell carcinoma of oral cavity, oropharynx, paranasal sinuses, hypopharynx, or larynx that is not amenable to local therapy with curative intent. Squamous cell carcinoma of unknown primary in ce...
Study Population: Patients with histologically or cytologically confirmed recurrent or metastatic squamous cell carcinoma of oral cavity, oropharynx, paranasal sinuses, hypopharynx, or larynx that is not amenable to local therapy with curative intent. Squamous cell carcinoma of unknown primary in cervical lymph node can be included only if p16 status is positive.
Tracking Information
- NCT #
- NCT03381183
- Collaborators
- Brooklyn ImmunoTherapeutics, LLC
- AstraZeneca
- Investigators
- Principal Investigator: Christine Chung, M.D. H. Lee Moffitt Cancer Center and Research Institute
Get Well Soon